This represents the first pineal GBM cohort defined under 2021 WHO classification. Our findings highlight the heterogeneity of outcomes, underscoring the need for molecular and epigenetic stratification to refine prognostication and therapeutic decision-making.
Clerkin et al. (Wed,) studied this question.